Form 4 for RNAC Cartesian Therapeutics, Inc.
Accepted 2023-01-04 00:00:00 ET · period of report 2023-01-02 · accession 0001453687-23-000022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-04 | 2023-01-02 | RNAC | Brunn Carsten | Pres, CEO, Dir | A - Grant | $0.00 | +282.8K | 827.1K | +52% | $0 |
| D | 2023-01-04 | 2023-01-02 | RNAC | Brunn Carsten | Pres, CEO, Dir | A - Grant | $0.00 | +1.27M | 1.27M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-02 | A | A | 282,800 | $0.00 | 827,083 | D | — | — | |
| 2 | Derivative | Employee Stock Option (right to buy) | 2023-01-02 | A | A | 1,275,000 | $0.00 | 1,275,000 | D | $1.13 · — to 2033-01-01 | 1,275,000 Common Stock | (F2) This option vests as to 25% on January 2, 2024. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. |